-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
HONG KONG, March 4, 2022 /PRNewswire/ -- Luye Pharma Group announced that its innovative anti-tumor drug, Lurbinectedin, licensed by PharmaMar, has submitted an NDA in Hong Kong, China, for the treatment of patients receiving platinum-based chemotherapy Adult patients with relapsed small cell lung cancer (SCLC) with disease progression during or after the disease
The NDA is based on the accelerated approval of Lurbinectedin from the U.
Lung cancer is a malignant tumor with high morbidity and mortality worldwide, among which small cell lung cancer accounts for about 13%-17% of all lung cancer patients
In 2019, Luye Pharma entered into an R&D and commercialization agreement with PharmaMar to obtain the exclusive rights to develop and commercialize Lurbinectedin in China, including all indications for small cell lung cancer
Yang Rongbing, President of Luye Pharma Group, said: "The incidence and mortality of lung cancer in China ranks first among malignant tumors [2], and among them, small cell lung cancer has a high degree of malignancy and strong invasiveness, and there are large unexplained diseases.
[1] Guidelines Working Committee of Chinese Society of Clinical Oncology.
[2] World Health Organization International Agency for Research on Cancer (IARC).
About Lurbinectedin
Lurbinectedin is a derivative of the marine compound ET-736 isolated from the sea squirt Ecteinacidia turbinata, the hydrogen atom in ET-736 is replaced by a methoxy group
To date, Lurbinectedin has received accelerated approval in the United States and provisional approval in Australia, the United Arab Emirates, Canada, and Singapore for the treatment of adult patients with recurrent small cell lung cancer who have progressed during or after platinum-based chemotherapy
About Luye Pharma Group
Luye Pharma Group is an international pharmaceutical company dedicated to the research, development, production and sales of innovative drugs
Luye Pharma has a deep layout of the global supply chain system.
Source: Luye Pharma
The original is abridged
